



SPAR NORD BANK A/S
(incorporated as a public limited liability company in Denmark)
€2,000,000,000
Euro Medium Term Note Programme

This Supplement (the “**Supplement**”) to the Prospectus dated 24 April 2024 (the “**Prospectus**”), which comprises a base prospectus for the purposes of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”), constitutes a supplement to the Prospectus for the purposes of Article 23 of the Prospectus Regulation and is prepared in connection with the €2,000,000,000 Euro Medium Term Note Programme established by Spar Nord Bank A/S (the “**Issuer**”).

Terms defined in the Prospectus have the same meaning when used in this Supplement.

This Supplement is supplemental to, and should be read in conjunction with, the Prospectus and any other supplements to the Prospectus issued by the Issuer.

This Supplement has been approved by the Central Bank of Ireland, as competent authority under the Prospectus Regulation. The Central Bank of Ireland only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or of the quality of the Notes that are the subject of this Supplement. Investors should make their own assessment as to the suitability of investing in the Notes.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Purpose of this Supplement

The purpose of this Supplement is to (a) incorporate by reference the interim unaudited consolidated financial statements of the Issuer for the six-month period ended 30 June 2024 and (b) include a new “Significant or Material Adverse Change” statement.

Documents incorporated by reference

The following document which has previously been published or is published simultaneously with this Supplement and has been filed with the Central Bank of Ireland shall, by virtue of this Supplement, be incorporated in, and form part of, the Prospectus:

- (a) the interim unaudited consolidated financial statements of the Issuer for the six-month period ended 30 June 2024 (the “**Q2 2024 Interim Report**”) (an English translation is available on the website of the Issuer at https://media.sparnord.dk/com/investor/financial_communication/reports/2024/Q2_2024_eng.pdf), excluding the sections “Outlook for 2024” on pages 3 and 11.

Such document, by virtue of this Supplement, shall be incorporated in, and form part of, the Prospectus, save that any statement contained in the document which is incorporated by reference herein shall be modified or superseded for the purpose of the Prospectus to the extent that a statement contained herein modifies or supersedes such earlier statement (whether expressly, by implication or otherwise). Any statement so modified or superseded shall not, except as so modified

or superseded, constitute a part of the Prospectus. Any documents themselves incorporated by reference in the document incorporated by reference in the Prospectus by virtue of this Supplement shall not form part of the Prospectus.

Those parts of the Q2 2024 Interim Report which are not specifically incorporated by reference in the Prospectus by virtue of this Supplement, are either not relevant for investors in the Notes or are covered elsewhere in the Prospectus.

The Q2 2024 Interim Report has been translated into English and represents a direct and accurate translation from the Danish language original. If there are any inconsistencies or discrepancies between the Danish language version and the English translation thereof, the original Danish language version shall prevail.

Significant or Material Adverse Change

Paragraph 3 of the “General Information” section on page 147 of the Prospectus shall be amended to read as follows:

“3. There has been no significant change in the financial performance or position of the Issuer or the Group since 30 June 2024 nor has there been any material adverse change in the financial position or prospects of the Issuer since 31 December 2023.”.

General

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference in the Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus since the publication of the Prospectus.